O-1602

O-1602 is an agonist of GPR55 (G protein-coupled receptor 55) . O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine) . O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1[1].

Product Specifications

CAS Number

[317321-41-8]

UNSPSC

12352005

Hazard Statement

H225, H319, H336

Target

GPR55

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/o-1602.html

Concentration

10mM

Purity

99.68

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C([C@H]2[C@@H](CCC(C)=C2)C(C)=C)C(O)=CC(O)=C1

Molecular Formula

C17H22O2

Molecular Weight

258.36

Precautions

H225, H319, H336

References & Citations

[1]Jinlong Zhang, et al. GPR55 activation improves anxiety- and depression-like behaviors of mice during methamphetamine withdrawal.Heliyon, 10 (2024), e30462.|[2]A. Díaz-Arteaga, et al. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes, Obesity and Metabolism. March 2012, Volume14, Issue3.|[3]Peng Ma, et al. IAVPGEVA: Orally Available DPP4-Targeting Soy Glycinin Derived Octapeptide with Therapeutic Potential in Nonalcoholic Steatohepatitis.Journal of Agricultural and Food Chemistry. 2024, 72, 13, 7167–7178.